(La Jolla, California) The Burnham Institute's Jeffrey Smith, Ph.D. has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors. These results will be published in the journal Cancer Research on March 15.
The metabolism of a tumor cell is different from its normal counterpart cell. Scientists have long suspected that metabolism is connected to tumor progression. Dr. Smith and co-workers designed a proteomics screen based on monitoring the activity of a family of enzymes--serine hydrolyases--involved in metabolism. They used their screen to compare normal prostate cells with prostate cancer cells and discovered that the prostate cancer cells are affected by an increased activity of fatty acid synthase. Fatty acid synthase is the enzyme that converts dietary carbohydrate to fat.
The screen also identified orlistat, marketed by Roche as XenicalTM, as an inhibitor of fatty acid synthase.
These discoveries, made in vitro, held true when tested in mice. When they administered orlistat to mice bearing prostate tumors, the Smith laboratory discovered that the drug was able to inhibit tumor growth in mice. Further experiments confirmed that orlistat has no effect on normal prostate cells and no apparent side effects in the mice; it acts specifically as fatty acid synthase.
Additional screening of breast cancer and colon cancer cells revealed that fatty acid synthase activity is upregulated in these tumors, as well, presenting the possibility of designing new treatments for these cancers based on inhibiting the enzyme's activity with orlistat or a new drug based on orlistat's inhibitory activity.
Orlistat was originally developedPage: 1 2 3 Related biology news :1
Contact: Nancy Beddingfield
. Obesity and hypertension: Two epidemics or one?2
. Obesity alone not a good predictor of cardiovascular risk and death, fat distribution proved best3
. Obesity and blood pressure4
. Obesity, kidney genetics, erectile dysfunction among highlighted research at APS Meeting5
. Obesity in Costa Rican children alarming, likely future health burden6
. Obesity prevention program aimed at second graders7
. Obesity not a personal failing, but a battle against biology8
. Obesity sleuths find chronic diseases linked to behavior contrary our DNA9
. Obesity...by choice10
. Obesity may exacerbate a heart disorder in African American females11
. Obesity has reached epidemic proportions - urgent need for research